Ribosomal Proteins in Cell Biology and Cancer

Abstract

Ribosomal proteins (RPs), long regarded as essential structural components of the ribosome, are now increasingly appreciated as multifunctional regulators that extend beyond their canonical roles in protein synthesis. They actively modulate key cellular processes, including transcription, DNA damage response, cell cycle progression, and stress signaling, thereby influencing both physiological homeostasis and disease states. Despite substantial advances in structural and functional characterization, the mechanistic underpinnings linking RP dysregulation to human pathogenesis remain incompletely defined, constituting a significant gap in our understanding. This review synthesizes recent evidence illuminating the dual nature of RPs in health and disease, with a particular emphasis on cancer. Under conditions of ribosomal stress, RPs activate tumor-suppressive pathways, whereas their dysregulation can promote oncogenesis. Beyond cancer, RPs' defects contribute to ribosomopathies, neurodegenerative disorders, and inflammation, highlighting their broad pathophysiological relevance. We also evaluate the translational potential of RPs as diagnostic and prognostic biomarkers, and review emerging therapeutic strategies targeting ribosomal pathways. Finally, we discuss current challenges, such as context-dependent RP functions, ribosome heterogeneity, and therapeutic specificity. By integrating mechanistic insights with translational prospects, this review positions RPs as pivotal nodes bridging fundamental biology and clinical application, offering a conceptual framework to guide precision medicine efforts in RP-associated diseases.

Keywords

cancer / Diamond-Blackfan anemia / P53 / ribosomal biosynthesis / ribosomal proteins

References

[1] J. P. Armache, A. Jarasch, A. M. Anger, et al., “Cryo-EM Structure and rRNA Model of a Translating Eukaryotic 80S Ribosome at 5.5-Å Resolution,” Proceedings of the National Academy of Sciences 107, no. 46 (2010): 19748–19753.

[2] S. Klinge, F. Voigts-Hoffmann, M. Leibundgut, and N. Ban, “Atomic Structures of the Eukaryotic Ribosome,” Trends in Biochemical Sciences 37, no. 5 (2012): 189–198.

[3] N. Ban, P. Nissen, J. Hansen, P. B. Moore, and T. A. Steitz, “The Complete Atomic Structure of the Large Ribosomal Subunit at 2.4 Å Resolution,” Science 289, no. 5481 (2000): 905–920.

[4] C. M. T. Spahn, R. Beckmann, N. Eswar, et al., “Structure of the 80S Ribosome From Saccharomyces Cerevisiae—tRNA-Ribosome and Subunit-Subunit Interactions,” Cell 107, no. 3 (2001): 373–386.

[5] D. J. Taylor, B. Devkota, A. D. Huang, et al., “Comprehensive Molecular Structure of the Eukaryotic Ribosome,” Structure 17, no. 12 (2009): 1591–1604.

[6] S. Mizushima and M. Nomura, “Assembly Mapping of 30S Ribosomal Proteins From E. coli,” Nature 226, no. 5252 (1970): 1214–1218.

[7] S. Fogel and P. S. Sypherd, “Chemical Basis for Heterogeneity of Ribosomal Proteins,” Proceedings of the National Academy of Sciences 59, no. 4 (1968): 1329–1336.

[8] W. Möller and H. Castleman, “Primary Structure Heterogeneity in Ribosomal Proteins From Escherichia coli,” Nature 215, no. 5107 (1967): 1293–1295.

[9] E. K. Y. Leung, N. Suslov, N. Tuttle, R. Sengupta, and J. A. Piccirilli, “The Mechanism of Peptidyl Transfer Catalysis by the Ribosome,” Annual Review of Biochemistry 80 (2011): 527–555.

[10] A. Liljas and M. Garber, “Ribosomal Proteins and Elongation Factors,” Current Opinion in Structural Biology 5, no. 6 (1995): 721–727.

[11] D. N. Wilson and K. H. Nierhaus, “Ribosomal Proteins in the Spotlight,” Critical Reviews in Biochemistry and Molecular Biology 40, no. 5 (2005): 243–267.

[12] A. Vanden Broeck and S. Klinge, “Eukaryotic Ribosome Assembly,” Annual Review of Biochemistry 93, no. 1 (2024): 189–210.

[13] J. A. Doudna and V. L. Rath, “Structure and Function of the Eukaryotic Ribosome,” Cell 109, no. 2 (2002): 153–156.

[14] S. Caldarola, M. C. De Stefano, F. Amaldi, and F. Loreni, “Synthesis and Function of Ribosomal Proteins—Fading Models and New Perspectives,” FEBS Journal 276, no. 12 (2009): 3199–3210.

[15] X. Zhou, W. J. Liao, J. M. Liao, P. Liao, and H. Lu, “Ribosomal Proteins: Functions Beyond the Ribosome,” Journal of Molecular Cell Biology 7, no. 2 (2015): 92–104.

[16] R. B. Bhavsar, L. N. Makley, and P. A. Tsonis, “The Other Lives of Ribosomal Proteins,” Human genomics 4, no. 5 (2010): 327–344.

[17] I. G. Wool, “Extraribosomal Functions of Ribosomal Proteins,” Trends in Biochemical Sciences 21, no. 5 (1996): 164–165.

[18] C. Petibon, M. Malik Ghulam, M. Catala, and S. Abou Elela, “Regulation of Ribosomal Protein Genes: An Ordered Anarchy,” WIREs RNA 12, no. 3 (2021): e1632.

[19] J. R. Warner and K. B. McIntosh, “How Common Are Extraribosomal Functions of Ribosomal Proteins?,” Molecular Cell 34, no. 1 (2009): 3–11.

[20] Y. Hong, Q. Lin, Y. Zhang, J. Liu, and Z. Zheng, “Research Progress of Ribosomal Proteins in Reproductive Development,” International Journal of Molecular Sciences 25, no. 23 (2024): 13151.

[21] S. J. Anderson, J. P. H. Lauritsen, M. G. Hartman, et al., “Ablation of Ribosomal Protein L22 Selectively Impairs αβ T Cell Development by Activation of a p53-Dependent Checkpoint,” Immunity 26, no. 6 (2007): 759–772.

[22] Y. Liu, C. Deisenroth, and Y. Zhang, “RP-MDM2-p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance,” Trends in Cancer 2, no. 4 (2016): 191–204.

[23] S. Tagnères, P. E. Santo, J. Radermecker, et al., “SURF2 Is a MDM2 Antagonist in Triggering the Nucleolar Stress Response,” Nature Communications 15, no. 1 (2024): 8404.

[24] S. C. Miller, C. C. MacDonald, M. K. Kellogg, Z. N. Karamysheva, and A. L. Karamyshev, “Specialized Ribosomes in Health and Disease,” International Journal of Molecular Sciences 24, no. 7 (2023): 6334.

[25] K. R. Kampen, S. O. Sulima, S. Vereecke, and K. De Keersmaecker, “Hallmarks of Ribosomopathies,” Nucleic Acids Research 48, no. 3 (2020): 1013–1028.

[26] M. C. Lafita-Navarro and M. Conacci-Sorrell, “Nucleolar Stress: From Development to Cancer,” Seminars in Cell & Developmental Biology 136 (2023): 64–74.

[27] Y. Lu, S. Wang, and Y. Jiao, “The Effects of Deregulated Ribosomal Biogenesis in Cancer,” Biomolecules 13, no. 11 (2023): 1593.

[28] J. Baßler and E. Hurt, “Eukaryotic Ribosome Assembly,” Annual Review of Biochemistry 88 (2019): 281–306.

[29] J. de la Cruz, K. Karbstein, and J. L. Woolford,., “Functions of Ribosomal Proteins in Assembly of Eukaryotic Ribosomes In Vivo,” Annual Review of Biochemistry 84 (2015): 93–129.

[30] T. Moss, “At the Crossroads of Growth Control; Making Ribosomal RNA,” Current Opinion in Genetics & Development 14, no. 2 (2004): 210–217.

[31] S. Klinge and J. L. Woolford,., “Ribosome Assembly Coming Into Focus,” Nature Reviews Molecular Cell Biology 20, no. 2 (2019): 116–131.

[32] R. Nazar, “Ribosomal RNA Processing and Ribosome Biogenesis in Eukaryotes,” IUBMB Life 56, no. 8 (2004): 457–465.

[33] A. K. Henras, J. Soudet, M. Gérus, et al., “The Post-Transcriptional Steps of Eukaryotic Ribosome Biogenesis,” Cellular and Molecular Life Sciences 65, no. 15 (2008): 2334–2359.

[34] F. Catez, N. Dalla Venezia, V. Marcel, C. Zorbas, D. L. J. Lafontaine, and J. J. Diaz, “Ribosome Biogenesis: An Emerging Druggable Pathway for Cancer Therapeutics,” Biochemical Pharmacology 159 (2019): 74–81.

[35] Y. Luan, N. Tang, J. Yang, et al., “Deficiency of Ribosomal Proteins Reshapes the Transcriptional and Translational Landscape in Human Cells,” Nucleic Acids Research 50, no. 12 (2022): 6601–6617.

[36] P. B. Moore and T. A. Steitz, “The Structural Basis of Large Ribosomal Subunit Function,” Annual Review of Biochemistry 72 (2003): 813–850.

[37] H. J. Kim, P. Maiti, and A. Barrientos, “Mitochondrial Ribosomes in Cancer,” Seminars in Cancer Biology 47 (2017): 67–81.

[38] S. Boulon, B. J. Westman, S. Hutten, F. M. Boisvert, and A. I. Lamond, “The Nucleolus Under Stress,” Molecular Cell 40, no. 2 (2010): 216–227.

[39] D. G. Pestov, Ž. Strezoska, and L. F. Lau, “Evidence of p53-Dependent Cross-Talk Between Ribosome Biogenesis and the Cell Cycle: Effects of Nucleolar Protein Bop1 on G(1)/S Transition,” Molecular and Cellular Biology 21, no. 13 (2001): 4246–4255.

[40] A. Pecoraro, M. Pagano, G. Russo, and A. Russo, “Ribosome Biogenesis and Cancer: Overview on Ribosomal Proteins,” International Journal of Molecular Sciences 22, no. 11 (2021): 5496.

[41] M. Seidel, N. Romanov, A. Obarska-Kosinska, et al., “Co-Translational Binding of Importins to Nascent Proteins,” Nature Communications 14, no. 1 (2023): 3418.

[42] P. Stelter, F. M. Huber, R. Kunze, D. Flemming, A. Hoelz, and E. Hurt, “Coordinated Ribosomal L4 Protein Assembly Into the Pre-Ribosome Is Regulated by Its Eukaryote-Specific Extension,” Molecular Cell 58, no. 5 (2015): 854–862.

[43] B. Pillet, J. J. García-Gómez, P. Pausch, et al., “The Dedicated Chaperone Acl4 Escorts Ribosomal Protein Rpl4 to Its Nuclear Pre-60S Assembly Site,” PLoS Genetics 11, no. 10 (2015): e1005565.

[44] A. M. Landry-Voyer, D. Bergeron, C. Yague-Sanz, B. Baker, and F. Bachand, “PDCD2 Functions as an Evolutionarily Conserved Chaperone Dedicated for the 40S Ribosomal Protein uS5 (RPS2),” Nucleic Acids Research 48, no. 22 (2020): 12900–12916.

[45] M. C. Yeh, N. H. Hsu, H. Y. Chu, et al., “Dual Protection by Bcp1 and Rkm1 Ensures Incorporation of uL14 Into Pre-60S Ribosomal Subunits,” Journal of Cell Biology 223, no. 8 (2024): e202306117.

[46] A. Narla and B. L. Ebert, “Ribosomopathies: Human Disorders of Ribosome Dysfunction,” Blood 115, no. 16 (2010): 3196–3205.

[47] S. V. Bhoopalan, T. Mayuranathan, N. Liu, et al., “Preclinical Development of Lentiviral Vector Gene Therapy for Diamond-Blackfan Anemia Syndrome,” Molecular Therapy 33, no. 7 (2025): 3086–3100.

[48] N. J. Boon, R. A. Oliveira, P. R. Körner, et al., “DNA Damage Induces p53-Independent Apoptosis Through Ribosome Stalling,” Science 384, no. 6697 (2024): 785–792.

[49] A. C. Vind, F. L. Zhong, and S. Bekker-Jensen, “Death by Ribosome,” Trends in Cell Biology 35, no. 7 (2025): 615–626.

[50] K. S. Robinson, G. A. Toh, P. Rozario, et al., “ZAKα-Driven Ribotoxic Stress Response Activates the Human NLRP1 Inflammasome,” Science 377, no. 6603 (2022): 328–335.

[51] G. Snieckute, L. Ryder, A. C. Vind, et al., “ROS-Induced Ribosome Impairment Underlies ZAKα-Mediated Metabolic Decline in Obesity and Aging,” Science 382, no. 6675 (2023): eadf3208.

[52] N. K. Sinha, C. McKenney, Z. Y. Yeow, et al., “The Ribotoxic Stress Response Drives UV-Mediated Cell Death,” Cell 187, no. 14 (2024): 3652–3670.e40.

[53] T. Maehama, M. Nishio, J. Otani, T. W. Mak, and A. Suzuki, “Nucleolar Stress: Molecular Mechanisms and Related Human Diseases,” Cancer Science 114, no. 5 (2023): 2078–2086.

[54] C. Otto, C. Kastner, S. Schmidt, et al., “RNA Polymerase I Inhibition Induces Terminal Differentiation, Growth Arrest, and Vulnerability to Senolytics in Colorectal Cancer Cells,” Molecular Oncology 16, no. 15 (2022): 2788–2809.

[55] N. M. Castillo Duque de Estrada, M. Thoms, D. Flemming, et al., “Structure of Nascent 5S RNPs at the Crossroad Between Ribosome Assembly and MDM2-p53 Pathways,” Nature Structural & Molecular Biology 30, no. 8 (2023): 1119–1131.

[56] S. P. Hwang and C. Denicourt, “The Impact of Ribosome Biogenesis in Cancer: From Proliferation to Metastasis,” NAR Cancer 6, no. 2 (2024): zcae017.

[57] K. E. Bohnsack and M. T. Bohnsack, “Uncovering the Assembly Pathway of Human Ribosomes and Its Emerging Links to Disease,” EMBO Journal 38, no. 13 (2019): e100278.

[58] J. Kang, N. Brajanovski, K. T. Chan, J. Xuan, R. B. Pearson, and E. Sanij, “Ribosomal Proteins and Human Diseases: Molecular Mechanisms and Targeted Therapy,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 323.

[59] Y. Ishihara, K. Nakamura, S. Nakagawa, et al., “Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers,” International Journal of Molecular Sciences 23, no. 24 (2022): 15986.

[60] W. Szaflarski, M. Leśniczak-Staszak, M. Sowiński, et al., “Early rRNA Processing Is a Stress-Dependent Regulatory Event Whose Inhibition Maintains Nucleolar Integrity,” Nucleic Acids Research 50, no. 2 (2022): 1033–1051.

[61] H. Mende and S. Müller, “Surveillance of Nucleolar Homeostasis and Ribosome Maturation by Autophagy and the Ubiquitin-Proteasome System,” Matrix Biology 100–101 (2021): 30–38.

[62] C. Recasens-Alvarez, C. Alexandre, J. Kirkpatrick, et al., “Ribosomopathy-Associated Mutations Cause Proteotoxic Stress That Is Alleviated by TOR Inhibition,” Nature Cell Biology 23, no. 2 (2021): 127–135.

[63] Y. M. Yang and K. Karbstein, “Ribosome Assembly and Repair,” Annual Review of Cell and Developmental Biology 40, no. 1 (2024): 241–264.

[64] Y. M. Yang and K. Karbstein, “The Chaperone Tsr2 Regulates Rps26 Release and Reincorporation From Mature Ribosomes to Enable a Reversible, Ribosome-Mediated Response to Stress,” Science Advances 8, no. 8 (2022): eabl4386.

[65] Y. M. Yang, Y. Jung, D. Abegg, A. Adibekian, K. S. Carroll, and K. Karbstein, “Chaperone-Directed Ribosome Repair After Oxidative Damage,” Molecular Cell 83, no. 9 (2023): 1527–1537.e5.

[66] Y. Zhang and H. Lu, “Signaling to p53: Ribosomal Proteins Find Their Way,” Cancer Cell 16, no. 5 (2009): 369–377.

[67] M. A. E. Lohrum, R. L. Ludwig, M. H. G. Kubbutat, M. Hanlon, and K. H. Vousden, “Regulation of HDM2 Activity by the Ribosomal Protein L11,” Cancer Cell 3, no. 6 (2003): 577–587.

[68] J. Chen, J. Lin, and A. J. Levine, “Regulation of Transcription Functions of the p53 Tumor Suppressor by the Mdm-2 Oncogene,” Molecular Medicine 1, no. 2 (1995): 142–152.

[69] L. T. Vassilev, B. T. Vu, B. Graves, et al., “In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2,” Science 303, no. 5659 (2004): 844–848.

[70] Y. Hu, Y. Qiu, E. Yagüe, W. Ji, J. Liu, and J. Zhang, “miRNA-205 Targets VEGFA and FGF2 and Regulates Resistance to Chemotherapeutics in Breast Cancer,” Cell Death & Disease 7, no. 6 (2016): e2291.

[71] S. Fumagalli, V. V. Ivanenkov, T. Teng, and G. Thomas, “Suprainduction of p53 by Disruption of 40S and 60S Ribosome Biogenesis Leads to the Activation of a Novel G2/M Checkpoint,” Genes & Development 26, no. 10 (2012): 1028–1040.

[72] K. E. Sloan, M. T. Bohnsack, and N. J. Watkins, “The 5S RNP Couples p53 Homeostasis to Ribosome Biogenesis and Nucleolar Stress,” Cell Reports 5, no. 1 (2013): 237–247.

[73] S. Bursać, M. C. Brdovčak, M. Pfannkuchen, et al., “Mutual Protection of Ribosomal Proteins L5 and L11 From Degradation Is Essential for p53 Activation Upon Ribosomal Biogenesis Stress,” Proceedings of the National Academy of Sciences 109, no. 50 (2012): 20467–20472.

[74] S. Fumagalli, A. Di Cara, A. Neb-Gulati, et al., “Absence of Nucleolar Disruption After Impairment of 40S Ribosome Biogenesis Reveals an rpL11-Translation-Dependent Mechanism of p53 Induction,” Nature Cell Biology 11, no. 4 (2009): 501–508.

[75] B. Mahata, A. Sundqvist, and D. P. Xirodimas, “Recruitment of RPL11 at Promoter Sites of p53-Regulated Genes Upon Nucleolar Stress Through NEDD8 and in an Mdm2-Dependent Manner,” Oncogene 31, no. 25 (2012): 3060–3071.

[76] C. J. Black, E. R. Thakur, L. A. Houghton, E. M. M. Quigley, P. Moayyedi, and A. C. Ford, “Efficacy of Psychological Therapies for Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis,” Gut 69, no. 8 (2020): 1441–1451.

[77] Z. Lei, Y. Luo, Q. Fu, et al., “Ribosomal Protein L6 Suppresses Hepatocellular Carcinoma by Modulating FBXO22-Mediated p53 Degradation,” Cellular Signalling 127 (2025): 111612.

[78] J. Jansen, K. E. Bohnsack, S. Böhlken-Fascher, M. T. Bohnsack, and M. Dobbelstein, “The Ribosomal Protein L22 Binds the MDM4 Pre-mRNA and Promotes Exon Skipping to Activate p53 Upon Nucleolar Stress,” Cell Reports 43, no. 8 (2024): 114610.

[79] G. W. Agak, A. Mouton, R. M. B. Teles, et al., “Extracellular Traps Released by Antimicrobial TH17 Cells Contribute to Host Defense,” Journal of Clinical Investigation 131, no. 2 (2021): e141594.

[80] S. Yadavilli, L. D. Mayo, M. Higgins, S. Lain, V. Hegde, and W. A. Deutsch, “Ribosomal Protein S3: A Multi-Functional Protein That Interacts With Both p53 and MDM2 Through Its KH Domain,” DNA Repair 8, no. 10 (2009): 1215–1224.

[81] A. Forslund, Z. Zeng, L. X. Qin, et al., “MDM2 Gene Amplification Is Correlated to Tumor Progression but Not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers,” Molecular Cancer Research 6, no. 2 (2008): 205–211.

[82] X. Meng, N. R. Tackmann, S. Liu, et al., “RPL23 Links Oncogenic RAS Signaling to p53-Mediated Tumor Suppression,” Cancer Research 76, no. 17 (2016): 5030–5039.

[83] G. Shaulsky, N. Goldfinger, M. S. Tosky, A. J. Levine, and V. Rotter, “Nuclear Localization Is Essential for the Activity of p53 Protein,” Oncogene 6, no. 11 (1991): 2055–2065.

[84] M. Pearson, R. Carbone, C. Sebastiani, et al., “PML Regulates p53 Acetylation and Premature Senescence Induced by Oncogenic Ras,” Nature 406, no. 6792 (2000): 207–210.

[85] R. Bernardi, P. P. Scaglioni, S. Bergmann, H. F. Horn, K. H. Vousden, and P. P. Pandolfi, “PML Regulates p53 Stability by Sequestering Mdm2 to the Nucleolus,” Nature Cell Biology 6, no. 7 (2004): 665–672.

[86] N. Xie, L. Ma, F. Zhu, et al., “Regulation of the MDM2-p53 Pathway by the Nucleolar Protein CSIG in Response to Nucleolar Stress,” Scientific Reports 6 (2016): 36171.

[87] R. Ajore, D. Raiser, M. McConkey, et al., “Deletion of Ribosomal Protein Genes Is a Common Vulnerability in Human Cancer, Especially in Concert With TP53 Mutations,” EMBO Molecular Medicine 9, no. 4 (2017): 498–507.

[88] I. Oršolić, S. Bursać, D. Jurada, et al., “Cancer-Associated Mutations in the Ribosomal Protein L5 Gene Dysregulate the HDM2/p53-Mediated Ribosome Biogenesis Checkpoint,” Oncogene 39, no. 17 (2020): 3443–3457.

[89] T. Stiewe, “The p53 Family in Differentiation and Tumorigenesis,” Nature Reviews Cancer 7, no. 3 (2007): 165–167.

[90] U. M. Moll and N. Slade, “p63 and p73: Roles in Development and Tumor Formation,” Molecular Cancer Research 2, no. 7 (2004): 371–386.

[91] X. Zhou, Q. Hao, Q. Zhang, et al., “Ribosomal Proteins L11 and L5 Activate TAp73 by Overcoming MDM2 Inhibition,” Cell Death & Differentiation 22, no. 5 (2015): 755–766.

[92] M. Zhang, J. Zhang, W. Yan, and X. Chen, “p73 Expression Is Regulated by Ribosomal Protein RPL26 Through mRNA Translation and Protein Stability,” Oncotarget 7, no. 48 (2016): 78255–78268.

[93] R. Dhanasekaran, A. Deutzmann, W. D. Mahauad-Fernandez, A. S. Hansen, A. M. Gouw, and D. W. Felsher, “The MYC Oncogene – The Grand Orchestrator of Cancer Growth and Immune Evasion,” Nature Reviews Clinical Oncology 19, no. 1 (2022): 23–36.

[94] M. S. Dai, H. Arnold, X. X. Sun, R. Sears, and H. Lu, “Inhibition of c-Myc Activity by Ribosomal Protein L11,” EMBO Journal 26, no. 14 (2007): 3332–3345.

[95] X. Zhou, Q. Hao, J. Liao, P. Liao, and H. Lu, “Ribosomal Protein S14 Negatively Regulates c-Myc Activity,” Journal of Biological Chemistry 288, no. 30 (2013): 21793–21801.

[96] M. Deschênes, M. Durand, M. A. Olivier, A. Pellerin-Viger, F. Rodier, and B. Chabot, “A Defective Splicing Machinery Promotes Senescence Through MDM4 Alternative Splicing,” Aging Cell 23, no. 11 (2024): e14301.

[97] W. Fan, H. Liu, G. C. Stachelek, et al., “Ribosomal RNA Transcription Regulates Splicing Through Ribosomal Protein RPL22,” Cell Chemical Biology 32, no. 7 (2025): 908–925.e9.

[98] H. N. W. Weinstein, K. Hu, L. Fish, et al., “RPL22 Is a Tumor Suppressor in MSI-High Cancers and a Splicing Regulator of MDM4,” Cell Reports 43, no. 8 (2024): 114622.

[99] S. Rao, K. Q. Cai, J. E. Stadanlick, et al., “Ribosomal Protein Rpl22 Controls the Dissemination of T-Cell Lymphoma,” Cancer Research 76, no. 11 (2016): 3387–3396.

[100] W. Tian, Y. Yang, L. Meng, et al., “GCDH Acetylation Orchestrates DNA Damage Response and Autophagy via Mitochondrial ROS to Suppress Hepatocellular Carcinoma Progression,” Research; A Journal of Science and Its Applications 8 (2025): 0862.

[101] S. Challa, B. R. Khulpateea, T. Nandu, et al., “Ribosome ADP-Ribosylation Inhibits Translation and Maintains Proteostasis in Cancers,” Cell 184, no. 17 (2021): 4531–4546.e26.

[102] X. Fan, Y. Wang, J. Song, et al., “MDM2 Inhibitor RG7388 Potently Inhibits Tumors by Activating p53 Pathway in Nasopharyngeal Carcinoma,” Cancer Biology & Therapy 20, no. 10 (2019): 1328–1336.

[103] Y. Zhu, J. Han, Y. Pan, et al., “Ribosomal Protein RPL7A Modulates Lung Adenocarcinoma Progression via circRANBP17-UPF1-Mediated SIRT6 Degradation,” Cellular & Molecular Biology Letters 30, no. 1 (2025): 145.

[104] R. Y. Ebright, S. Lee, B. S. Wittner, et al., “Deregulation of Ribosomal Protein Expression and Translation Promotes Breast Cancer Metastasis,” Science 367, no. 6485 (2020): 1468–1473.

[105] A. Y. Hsu, Q. Huang, X. Pi, et al., “Neutrophil-Derived Vesicles Control Complement Activation to Facilitate Inflammation Resolution,” Cell 188, no. 6 (2025): 1623–1641.e26.

[106] I. Kisly, J. Remme, and T. Tamm, “Ribosomal Protein eL24, Involved in Two Intersubunit Bridges, Stimulates Translation Initiation and Elongation,” Nucleic Acids Research 47, no. 1 (2019): 406–420.

[107] F. Delvillani, G. Papiani, G. Dehò, and F. Briani, “S1 Ribosomal Protein and the Interplay Between Translation and mRNA Decay,” Nucleic Acids Research 39, no. 17 (2011): 7702–7715.

[108] Y. Matsuki, Y. Matsuo, Y. Nakano, et al., “Ribosomal Protein S7 Ubiquitination During ER Stress in Yeast Is Associated With Selective mRNA Translation and Stress Outcome,” Scientific Reports 10, no. 1 (2020): 19669.

[109] S. V. Bhoopalan, J. S. Yen, T. Mayuranathan, et al., “An RPS19-Edited Model for Diamond-Blackfan Anemia Reveals TP53-Dependent Impairment of Hematopoietic Stem Cell Activity,” JCI Insight 8, no. 1 (2023): e161810.

[110] L. Da Costa, T. Leblanc, and N. Mohandas, “Diamond-Blackfan Anemia,” Blood 136, no. 11 (2020): 1262–1273.

[111] C. Catalanotto, C. Barbato, C. Cogoni, and D. Benelli, “The RNA-Binding Function of Ribosomal Proteins and Ribosome Biogenesis Factors in Human Health and Disease,” Biomedicines 11, no. 11 (2023): 2969.

[112] N. Draptchinskaia, P. Gustavsson, B. Andersson, et al., “The Gene Encoding Ribosomal Protein S19 Is Mutated in Diamond-Blackfan Anaemia,” Nature Genetics 21, no. 2 (1999): 169–175.

[113] P. Jaako, S. Debnath, K. Olsson, et al., “Disruption of the 5S RNP-Mdm2 Interaction Significantly Improves the Erythroid Defect in a Mouse Model for Diamond-Blackfan Anemia,” Leukemia 29, no. 11 (2015): 2221–2229.

[114] T. Kamio, B. Gu, T. S. Olson, Y. Zhang, P. J. Mason, and M. Bessler, “Mice With a Mutation in the Mdm2 Gene That Interferes With MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis,” PLoS One 11, no. 4 (2016): e0152263.

[115] R. Cmejla, J. Blafkova, T. Stopka, et al., “Ribosomal Protein S19 Gene Mutations in Patients With Diamond-Blackfan Anemia and Identification of Ribosomal Protein S19 Pseudogenes,” Blood Cells, Molecules, and Diseases 26, no. 2 (2000): 124–132.

[116] A. Pelava, C. Schneider, and N. J. Watkins, “The Importance of Ribosome Production, and the 5S RNP-MDM2 Pathway, in Health and Disease,” Biochemical Society Transactions 44, no. 4 (2016): 1086–1090.

[117] V. G. Sankaran, R. Ghazvinian, R. Do, et al., “Exome Sequencing Identifies GATA1 Mutations Resulting in Diamond-Blackfan Anemia,” Journal of Clinical Investigation 122, no. 7 (2012): 2439–2443.

[118] L. S. Ludwig, H. T. Gazda, J. C. Eng, et al., “Altered Translation of GATA1 in Diamond-Blackfan Anemia,” Nature Medicine 20, no. 7 (2014): 748–753.

[119] D. Iskander, G. Wang, E. F. Heuston, et al., “Single-Cell Profiling of Human Bone Marrow Progenitors Reveals Mechanisms of Failing Erythropoiesis in Diamond-Blackfan Anemia,” Science Translational Medicine 13, no. 610 (2021): eabf0113.

[120] L. F. Lorenzo-Martín, J. Robles-Valero, R. Ramírez-Cota, et al., “Ribosomal Protein Deficiencies Linked to Diamond-Blackfan Anemia Induce Distinctive Alterations of ATF4 Expression,” iScience 28, no. 4 (2025): 112138.

[121] R. K. Khajuria, M. Munschauer, J. C. Ulirsch, et al., “Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis,” Cell 173, no. 1 (2018): 90–103.e19.

[122] Y. Liu and S. Karlsson, “Correction: Perspectives of Current Understanding and Therapeutics of Diamond-Blackfan Anemia,” Leukemia 38, no. 1 (2024): 228.

[123] A. Vlachos and E. Muir, “How I Treat Diamond-Blackfan Anemia,” Blood 116, no. 19 (2010): 3715–3723.

[124] J. Li, Y. Tang, P. M. K. Tang, et al., “Retracted: Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice,” Molecular Therapy 26, no. 10 (2018): 2523–2532.

[125] J. Lv, X. R. Huang, J. Klug, et al., “Ribosomal Protein S19 Is a Novel Therapeutic Agent in Inflammatory Kidney Disease,” Clinical Science 124, no. 10 (2013): 627–637.

[126] T. Yamamoto, “Roles of the Ribosomal Protein S19 Dimer and the C5a Receptor in Pathophysiological Functions of Phagocytic Leukocytes,” Pathology International 57, no. 1 (2007): 1–11.

[127] I. Revollo, H. Nishiura, Y. Shibuya, Y. Oda, N. Nishino, and T. Yamamoto, “Agonist and Antagonist Dual Effect of the Cross-Linked S19 Ribosomal Protein Dimer in the C5a Receptor-Mediated Respiratory Burst Reaction of Phagocytic Leukocytes,” Inflammation Research 54, no. 2 (2005): 82–90.

[128] Y. Li, B. Huang, H. Yang, et al., “Latexin Deficiency in Mice Up-Regulates Inflammation and Aggravates Colitis Through HECTD1/Rps3/NF-κB Pathway,” Scientific Reports 10, no. 1 (2020): 9868.

[129] R. Mukhopadhyay, P. S. Ray, A. Arif, A. K. Brady, M. Kinter, and P. L. Fox, “DAPK-ZIPK-L13a Axis Constitutes a Negative-Feedback Module Regulating Inflammatory Gene Expression,” Molecular Cell 32, no. 3 (2008): 371–382.

[130] Y. Jiang, S. Sun, Y. Quan, et al., “Nuclear RPSA Senses Viral Nucleic Acids to Promote the Innate Inflammatory Response,” Nature Communications 14, no. 1 (2023): 8455.

[131] Y. Duan, L. Zhang, D. Angosto-Bazarra, P. Pelegrín, G. Núñez, and Y. He, “RACK1 Mediates NLRP3 Inflammasome Activation by Promoting NLRP3 Active Conformation and Inflammasome Assembly,” Cell Reports 33, no. 7 (2020): 108405.

[132] F. Moadab, X. Wang, R. Najjar, et al., “Argonaute, Vault, and Ribosomal Proteins Targeted by Autoantibodies in Systemic Lupus Erythematosus,” Journal of Rheumatology 50, no. 9 (2023): 1136–1144.

[133] Q. Dong, H. Xu, P. Xu, J. Liu, Z. Shen, and Y. Li, “Silencing RPL11 Attenuates Acute Kidney Injury by Suppressing Tubular Apoptosis and Macrophage-Driven Inflammation,” Frontiers in Immunology 16 (2025): 1642446.

[134] Z. Wu, I. Tantray, J. Lim, et al., “MISTERMINATE Mechanistically Links Mitochondrial Dysfunction With Proteostasis Failure,” Molecular Cell 75, no. 4 (2019): 835–848.e8.

[135] S. Filbeck, F. Cerullo, S. Pfeffer, and C. A. P. Joazeiro, “Ribosome-Associated Quality-Control Mechanisms From Bacteria to Humans,” Molecular Cell 82, no. 8 (2022): 1451–1466.

[136] S. Rimal, Y. Li, R. Vartak, et al., “Inefficient Quality Control of Ribosome Stalling During APP Synthesis Generates CAT-Tailed Species That Precipitate Hallmarks of Alzheimer's Disease,” Acta Neuropathologica Communications 9, no. 1 (2021): 169.

[137] H. C. Hollis, A. Sharma, P. W. Sheehan, et al., “Reconstructed Cell-Type-Specific Rhythms in Human Brain Link Alzheimer's Pathology, Circadian Stress, and Ribosomal Disruption,” Neuron 113, no. 17 (2025): 2822–2838.e7.

[138] M. Suzuki, K. Tezuka, T. Handa, et al., “Upregulation of Ribosome Complexes at the Blood-Brain Barrier in Alzheimer's Disease Patients,” Journal of Cerebral Blood Flow & Metabolism 42, no. 11 (2022): 2134–2150.

[139] S. Ito, R. Yagi, S. Ogata, et al., “Proteomic Alterations in the Brain and Blood-Brain Barrier During Brain Aβ Accumulation in an APP Knock-In Mouse Model of Alzheimer's Disease,” Fluids and Barriers of the CNS 20, no. 1 (2023): 66.

[140] T. Alqahtani, S. L. Deore, A. A. Kide, et al., “Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease, and Parkinson's Disease, Huntington's Disease and Amyotrophic Lateral Sclerosis—An Updated Review,” Mitochondrion 71 (2023): 83–92.

[141] L. Del Giudice, P. Pontieri, M. Aletta, and M. Calcagnile, “Mitochondrial Neurodegenerative Diseases: Three Mitochondrial Ribosomal Proteins as Intermediate Stage in the Pathway That Associates Damaged Genes With Alzheimer's and Parkinson's,” Biology (Basel) 12, no. 7 (2023): 972.

[142] X. Rui, Z. Huang, R. Chen, Y. Chen, Y. Wang, and Z. Huang, “RPS3 Promotes the Metastasis and Cisplatin Resistance of Adenoid Cystic Carcinoma,” Frontiers in Oncology 12 (2022): 804439.

[143] Z. Liang, H. Liu, L. Xiong, et al., “A Novel NF-κB Regulator Encoded by circPLCE1 Inhibits Colorectal Carcinoma Progression by Promoting RPS3 Ubiquitin-Dependent Degradation,” Molecular Cancer 20, no. 1 (2021): 103.

[144] T. Wang, C. Jin, P. Yang, et al., “UBE2J1 Inhibits Colorectal Cancer Progression by Promoting Ubiquitination and Degradation of RPS3,” Oncogene 42, no. 9 (2023): 651–664.

[145] H. Nagao-Kitamoto, T. Setoguchi, S. Kitamoto, et al., “Ribosomal Protein S3 Regulates GLI2-Mediated Osteosarcoma Invasion,” Cancer Letters 356, no. 2 Pt B (2015): 855–861.

[146] W. Kim, H. Youn, S. Lee, et al., “RNF138-Mediated Ubiquitination of rpS3 Is Required for Resistance of Glioblastoma Cells to Radiation-Induced Apoptosis,” Experimental & Molecular Medicine 50, no. 1 (2018): e434.

[147] Z. Lei, Y. Luo, J. Lu, et al., “FBXO22 Promotes HCC Angiogenesis and Metastasis via RPS5/AKT/HIF-1α/VEGF-A Signaling Axis,” Cancer Gene Therapy 32, no. 2 (2025): 198–213.

[148] S. Bram Ednersson, M. Stenson, M. Stern, et al., “Expression of Ribosomal and Actin Network Proteins and Immunochemotherapy Resistance in Diffuse Large B Cell Lymphoma Patients,” British Journal of Haematology 181, no. 6 (2018): 770–781.

[149] M. Watanabe, S. Boku, K. Kobayashi, et al., “A Chemoproteoinformatics Approach Demonstrates That Aspirin Increases Sensitivity to MEK Inhibition by Directly Binding to RPS5,” PNAS Nexus 1, no. 2 (2022): pgac059.

[150] J. Hanroongsri, P. Amornphimoltham, R. H. Younis, and R. Chaisuparat, “Expression of PD-L1 and p-RPS6 in Epithelial Dysplasia and Squamous Cell Carcinoma of the Oral Cavity,” Frontiers in Oral Health 5 (2024): 1337582.

[151] M. M. Karg, L. John, N. Refaian, et al., “Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma,” Molecular Cancer Research 20, no. 8 (2022): 1320–1336.

[152] S. Grasso, E. Tristante, M. Saceda, et al., “Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines Is Mediated by p70S6K and RPS6 Activation,” Neoplasia 16, no. 10 (2014): 845–860.

[153] Y. Shirakawa, T. Hide, M. Yamaoka, et al., “Ribosomal Protein S6 Promotes Stem-Like Characters in Glioma Cells,” Cancer Science 111, no. 6 (2020): 2041–2051.

[154] V. Gambardella, F. Gimeno-Valiente, N. Tarazona, et al., “NRF2 Through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer,” Clinical Cancer Research 25, no. 5 (2019): 1639–1649.

[155] Y. Liu, J. Li, H. Ou, et al., “Identification of New Aptamer BC-3 Targeting RPS7 From Rapid Screening for Bladder Carcinoma,” Genes & Diseases 10, no. 5 (2023): 2137–2150.

[156] L. Wu, F. Kou, Z. Ji, et al., “SMYD2 Promotes Tumorigenesis and Metastasis of Lung Adenocarcinoma Through RPS7,” Cell Death & Disease 12, no. 5 (2021): 439.

[157] C. Liang, J. Zhou, Y. Wang, et al., “Essential Genes Analysis Reveals Small Ribosomal Subunit Protein eS28 May Be a Prognostic Factor and Potential Vulnerability in Osteosarcoma,” Journal of Bone Oncology 44 (2024): 100517.

[158] D. Cheng, B. Zhu, S. Li, T. Yuan, Q. Yang, and C. Fan, “Down-Regulation of RPS9 Inhibits Osteosarcoma Cell Growth Through Inactivation of MAPK Signaling Pathway,” Journal of Cancer 8, no. 14 (2017): 2720–2728.

[159] Y. Huang, M. Peng, H. Qin, et al., “LAPTM4B Promotes AML Progression Through Regulating RPS9/STAT3 Axis,” Cellular Signalling 106 (2023): 110623.

[160] Y. Kong, D. Shuangshuang, X. Liang, and X. Zhou, “RPS9 Promotes the Progression of NSCLC via Activation Stat3 and Erk Signaling Pathways,” Journal of Cancer 13, no. 4 (2022): 1346–1355.

[161] V. Sharma, A. Nandan, H. Singh, et al., “Events of Alternative Splicing in Head and Neck Cancer via RNA Sequencing – An Update,” BMC Genomics 20, no. 1 (2019): 442.

[162] Y. Zhang, J. Zhang, X. Chen, and Z. Yang, “Polymeric Immunoglobulin Receptor (PIGR) Exerts Oncogenic Functions via Activating Ribosome Pathway in Hepatocellular Carcinoma,” International Journal of Medical Sciences 18, no. 2 (2021): 364–371.

[163] E. Derenzini, C. Agostinelli, A. Rossi, et al., “Genomic Alterations of Ribosomal Protein Genes in Diffuse Large B Cell Lymphoma,” British Journal of Haematology 185, no. 2 (2019): 330–334.

[164] V. L. Katanaev, M. Kryuchkov, V. Averkov, et al., “HumanaFly: High-Throughput Transgenesis and Expression of Breast Cancer Transcripts in Drosophila Eye Discovers the RPS12-Wingless Signaling Axis,” Scientific Reports 10, no. 1 (2020): 21013.

[165] Y. Hu, J. Xu, J. Lv, et al., “Cellular Heterogeneity and Communication Networks in Gastric Cancer: Single-Cell Analysis Reveals β-Hydroxybutyrylation-Associated Genes and Immune Infiltration Characteristics,” Translational Oncology 53 (2025): 102270.

[166] X. Guo, Y. Shi, Y. Gou, et al., “Human Ribosomal Protein S13 Promotes Gastric Cancer Growth Through Down-Regulating p27(Kip1),” Journal of Cellular and Molecular Medicine 15, no. 2 (2011): 296–306.

[167] M. G. Denis, C. Chadeneau, M. T. Lecabellec, et al., “Over-Expression of the S13 Ribosomal Protein in Actively Growing Cells,” International Journal of Cancer 55, no. 2 (1993): 275–280.

[168] S. Hu, J. Cai, H. Fang, Z. Chen, J. Zhang, and R. Cai, “RPS14 Promotes the Development and Progression of Glioma via p53 Signaling Pathway,” Experimental Cell Research 423, no. 1 (2023): 113451.

[169] B. Tian, J. Zhou, G. Chen, T. Jiang, Q. Li, and J. Qin, “Downregulation of ZNF280A Inhibits Proliferation and Tumorigenicity of Colorectal Cancer Cells by Promoting the Ubiquitination and Degradation of RPS14,” Frontiers in Oncology 12 (2022): 906281.

[170] L. Han, Y. Huo, L. Huang, et al., “Genome-Wide Functional Integration Identified MAZ-Controlled RPS14 Dysregulation in Hepatocellular Carcinoma,” Archives of Toxicology 98, no. 3 (2024): 985–997.

[171] Z. Qian, J. M. Joslin, T. R. Tennant, et al., “Cytogenetic and Genetic Pathways in Therapy-Related Acute Myeloid Leukemia,” Chemico-Biological Interactions 184, no. 1–2 (2010): 50–57.

[172] M. Youn, H. Huang, C. Chen, et al., “MMP9 Inhibition Increases Erythropoiesis in RPS14-Deficient del(5q) MDS Models Through Suppression of TGF-β Pathways,” Blood Advances 3, no. 18 (2019): 2751–2763.

[173] H. Q. Yu, F. Li, H. Xiong, et al., “Elevated FBXL18 Promotes RPS15A Ubiquitination and SMAD3 Activation to Drive HCC,” Hepatology Communications 7, no. 7 (2023): e00198.

[174] L. Ding, M. Sun, Y. Sun, et al., “MCM8 Promotes Gastric Cancer Progression Through RPS15A and Predicts Poor Prognosis,” Cancer Medicine 13, no. 13 (2024): e7424.

[175] Y. Zhao, Y. Li, R. Zhu, et al., “RPS15 Interacted With IGF2BP1 to Promote Esophageal Squamous Cell Carcinoma Development via Recognizing m(6)A Modification,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 224.

[176] P. Guo, Y. Wang, C. Dai, et al., “Ribosomal Protein S15a Promotes Tumor Angiogenesis via Enhancing Wnt/β-Catenin-Induced FGF18 Expression in Hepatocellular Carcinoma,” Oncogene 37, no. 9 (2018): 1220–1236.

[177] T. Liu, J. Zhang, H. Chen, et al., “PSMC2 Promotes the Progression of Gastric Cancer via Induction of RPS15A/mTOR Pathway,” Oncogenesis 11, no. 1 (2022): 12.

[178] J. Xiao, X. Yu, F. Meng, et al., “Integrating Spatial and Single-Cell Transcriptomics Reveals Tumor Heterogeneity and Intercellular Networks in Colorectal Cancer,” Cell Death & Disease 15, no. 5 (2024): 326.

[179] C. Chen, W. Wang, C. Ning, et al., “Integrated Systematic Functional Screen and Fine-Mapping Decipher the Role and Genetic Regulation of RPS19 in Colorectal Cancer Development,” Archives of Toxicology 98, no. 10 (2024): 3453–3465.

[180] Z. Xie, S. Peng, J. Wang, et al., “Multi-Omics Analysis Reveals the Role of Ribosome Biogenesis in Malignant Clear Cell Renal Cell Carcinoma and the Development of a Machine Learning-Based Prognostic Model,” Frontiers in Immunology 16 (2025): 1602898.

[181] Y. Tian, E. S. Babaylova, A. V. Gopanenko, et al., “Changes in the Transcriptome Caused by Mutations in the Ribosomal Protein uS10 Associated With a Predisposition to Colorectal Cancer,” International Journal of Molecular Sciences 23, no. 11 (2022): 6174.

[182] C. Shen, Z. Chen, Y. Zhang, et al., “Biochemical and Clinical Effects of RPS20 Expression in Renal Clear Cell Carcinoma,” Oncology Reports 49, no. 1 (2022): 22.

[183] M. De Bortoli, R. C. Castellino, X. Y. Lu, et al., “Medulloblastoma Outcome Is Adversely Associated With Overexpression of EEF1D, RPL30, and RPS20 on the Long Arm of Chromosome 8,” BMC Cancer 6 (2006): 223.

[184] S. Bhar, F. Zhou, L. C. Reineke, et al., “Expansion of Germline RPS20 Mutation Phenotype to Include Diamond-Blackfan Anemia,” Human Mutation 41, no. 11 (2020): 1918–1930.

[185] Z. Liang, Q. Mou, Z. Pan, et al., “Identification of Candidate Diagnostic and Prognostic Biomarkers for Human Prostate Cancer: RPL22L1 and RPS21,” Medical Oncology 36, no. 6 (2019): 56.

[186] S. Wu, G. Wang, L. Gu, Y. Zhang, and Z. Wang, “RPS21 Enhances Hepatocellular Carcinoma Development Through GPX4 Stabilization,” Translational Oncology 51 (2025): 102189.

[187] J. Pan, C. Zhang, G. Sa, H. Huang, R. Zhang, and F. Chen, “Identification of Ribosomal Protein S21 as a Potential Prognostic and Immunotherapy Biomarker for Hepatocellular Carcinoma,” Asian Journal of Surgery 48 (2024): 137–149.

[188] J. Feldheim, A. F. Kessler, D. Schmitt, et al., “Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma—A New Disease Biomarker?,” Cancers 12, no. 5 (2020): 1085.

[189] D. Li, X. Zhou, W. Xu, et al., “High-Fat Diet Promotes Prostate Cancer Metastasis via RPS27,” Cancer & Metabolism 12, no. 1 (2024): 6.

[190] J. Zhang, P. Wang, T. Li, et al., “Exploration of RNA-Binding Proteins Identified RPS27 as a Potential Regulator Associated With Kaposi's Sarcoma Development,” BMC Cancer 25, no. 1 (2025): 362.

[191] L. Liao, Y. L. Zhang, L. Deng, et al., “Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer,” Cancer Research 83, no. 3 (2023): 471–484.

[192] X. Song, Z. Wei, C. Zhang, et al., “CircAKT3 Promotes Prostate Cancer Proliferation and Metastasis by Enhancing the Binding of RPS27A and RPL11,” Molecular Cancer 24, no. 1 (2025): 53.

[193] H. Li, H. Zhang, G. Huang, et al., “Loss of RPS27a Expression Regulates the Cell Cycle, Apoptosis, and Proliferation via the RPL11-MDM2-p53 Pathway in Lung Adenocarcinoma Cells,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 33.

[194] L. Chen and H. Wang, “Nicotine Promotes Human Papillomavirus (HPV)-Immortalized Cervical Epithelial Cells (H8) Proliferation by Activating RPS27a-Mdm2-P53 Pathway In Vitro,” Toxicological Sciences 167, no. 2 (2019): 408–418.

[195] A. You, W. Tian, H. Yuan, L. Gu, J. Zhou, and D. Deng, “TTC22 Promotes m6A-Mediated WTAP Expression and Colon Cancer Metastasis in an RPL4 Binding-Dependent Pattern,” Oncogene 41, no. 32 (2022): 3925–3938.

[196] X. Yang, L. Sun, L. Wang, B. Yao, H. Mo, and W. Yang, “LncRNA SNHG7 Accelerates the Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells via Regulating miR-122-5p and RPL4,” Biomedicine & Pharmacotherapy 118 (2019): 109386.

[197] L. Tong, K. Ye, Q. Chen, et al., “Proteomics Shows That Brain Metastases of Lung Adenocarcinoma Overexpress Ribosomal Proteins in Response to Gamma Knife Radiosurgery,” Scientific Reports 14, no. 1 (2024): 15646.

[198] W. Zhang, L. Liu, R. Chen, et al., “Ribosomal Protein L5 Induces Cellular Senescence via p53-p21-pRb Pathway to Mediate Relapse of Acute Myeloid Leukemia,” Scientific Reports 15, no. 1 (2025): 27649.

[199] Y. Li, Y. Zhou, B. Li, et al., “WDR74 Modulates Melanoma Tumorigenesis and Metastasis Through the RPL5-MDM2-p53 Pathway,” Oncogene 39, no. 13 (2020): 2741–2755.

[200] X. Hu, F. Li, Y. Zhou, et al., “DDX24 Promotes Metastasis by Regulating RPL5 in Non-Small Cell Lung Cancer,” Cancer Medicine 11, no. 23 (2022): 4513–4525.

[201] B. Ziccheddu, C. Giannotta, M. D'Agostino, et al., “Genomic and Immune Determinants of Resistance to Daratumumab-Based Therapy in Relapsed Refractory Multiple Myeloma,” Blood Cancer Journal 14, no. 1 (2024): 117.

[202] M. F. O'Donohue, L. Da Costa, M. Lezzerini, et al., “HEATR3 Variants Impair Nuclear Import of uL18 (RPL5) and Drive Diamond-Blackfan Anemia,” Blood 139, no. 21 (2022): 3111–3126.

[203] M. Yang, S. Cheng, H. Gu, et al., “RPL6 Interacts With HMGCS1 to Stabilize HIF-1α by Promoting Cholesterol Production in Hepatocellular Carcinoma,” Advanced Science 12, no. 38 (2025): e01373.

[204] H. Huang, C. Lin, C. Zhou, L. Cui, and Y. Rong, “The DIAPH3/RPL6 Axis Regulates the cGAS-STING Pathway in Pancreatic Cancer,” European Journal of Medical Research 31 (2025): 9.

[205] Y. Xi, Y. Huang, J. Hu, et al., “EIF2B5 Promotes Malignant Progression of Hepatocellular Carcinoma by Activating the PI3K/AKT Signaling Pathway Through Targeting RPL6,” Cellular Signalling 132 (2025): 111821.

[206] Y. Gao, Z. Wang, Y. Zhu, et al., “NOP2/Sun RNA Methyltransferase 2 Promotes Tumor Progression via Its Interacting Partner RPL6 in Gallbladder Carcinoma,” Cancer Science 110, no. 11 (2019): 3510–3519.

[207] J. Du, Y. Shi, Y. Pan, et al., “Regulation of Multidrug Resistance by Ribosomal Protein l6 in Gastric Cancer Cells,” Cancer Biology & Therapy 4, no. 2 (2005): 250–255.

[208] X. Tao, X. Wu, P. Zhou, et al., “UBE2T Promotes Glioblastoma Malignancy Through Ubiquitination-Mediated Degradation of RPL6,” Cancer Science 114, no. 2 (2023): 521–532.

[209] Y. Zhu, H. Lin, Z. Li, M. Wang, and J. Luo, “Modulation of Expression of Ribosomal Protein L7a (rpL7a) by Ethanol in Human Breast Cancer Cells,” Breast Cancer Research and Treatment 69, no. 1 (2001): 29–38.

[210] Y. Wang, D. Cheong, S. Chan, and S. C. Hooi, “Ribosomal Protein L7a Gene Is Up-Regulated but Not Fused to the Tyrosine Kinase Receptor as Chimeric Trk Oncogene in Human Colorectal Carcinoma,” International Journal of Oncology 16, no. 4 (2000): 757–762.

[211] R. Kroes, “The Identification of Novel Therapeutic Targets for the Treatment of Malignant Brain Tumors,” Cancer Letters 156, no. 2 (2000): 191–198.

[212] A. Li, J. Xie, L. Lv, et al., “RPL9 Acts as an Oncogene by Shuttling miRNAs Through Exosomes in Human Hepatocellular Carcinoma Cells,” International Journal of Oncology 64, no. 6 (2024): 58.

[213] A. R. Beyer, D. V. Bann, B. Rice, et al., “Nucleolar Trafficking of the Mouse Mammary Tumor Virus Gag Protein Induced by Interaction With Ribosomal Protein L9,” Journal of Virology 87, no. 2 (2013): 1069–1082.

[214] M. Lezzerini, M. Penzo, M. F. O'Donohue, et al., “Ribosomal Protein Gene RPL9 Variants Can Differentially Impair Ribosome Function and Cellular Metabolism,” Nucleic Acids Research 48, no. 2 (2020): 770–787.

[215] K. Wang, S. Chen, Y. Wu, et al., “The Ufmylation Modification of Ribosomal Protein L10 in the Development of Pancreatic Adenocarcinoma,” Cell Death & Disease 14, no. 6 (2023): 350.

[216] Y. Ren, C. Tao, X. Wang, and Y. Ju, “Identification of RPL5 and RPL10 as Novel Diagnostic Biomarkers of Atypical Teratoid/Rhabdoid Tumors,” Cancer Cell International 18 (2018): 190.

[217] J. Shi, L. Zhang, D. Zhou, et al., “Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer,” Journal of Cancer 9, no. 4 (2018): 745–756.

[218] T. Girardi, S. Vereecke, S. O. Sulima, et al., “The T-Cell Leukemia-Associated Ribosomal RPL10 R98S Mutation Enhances JAK-STAT Signaling,” Leukemia 32, no. 3 (2018): 809–819.

[219] K. R. Kampen, S. O. Sulima, B. Verbelen, et al., “The Ribosomal RPL10 R98S Mutation Drives IRES-Dependent BCL-2 Translation in T-ALL,” Leukemia 33, no. 2 (2019): 319–332.

[220] R. Uchi, R. Kogo, K. Kawahara, et al., “PICT1 Regulates TP53 via RPL11 and Is Involved in Gastric Cancer Progression,” British Journal of Cancer 109, no. 8 (2013): 2199–2206.

[221] L. Morgado-Palacin, G. Varetti, S. Llanos, G. Gómez-López, D. Martinez, and M. Serrano, “Partial Loss of Rpl11 in Adult Mice Recapitulates Diamond-Blackfan Anemia and Promotes Lymphomagenesis,” Cell Reports 13, no. 4 (2015): 712–722.

[222] J. Chen, Y. Li, J. Wu, Y. Liu, and S. Kang, “Whole-Exome Sequencing Reveals Potential Germline and Somatic Mutations in 60 Malignant Ovarian Germ Cell Tumors,” Biology of Reproduction 105, no. 1 (2021): 164–178.

[223] M. Y. Li, C. Zhao, L. Chen, et al., “Quantitative Proteomic Analysis of Plasma Exosomes to Identify the Candidate Biomarker of Imatinib Resistance in Chronic Myeloid Leukemia Patients,” Frontiers in Oncology 11 (2021): 779567.

[224] Y. Liu, X. Zhu, J. Zhu, et al., “Identification of Differential Expression of Genes in Hepatocellular Carcinoma by Suppression Subtractive Hybridization Combined cDNA Microarray,” Oncology Reports 18, no. 4 (2007): 943–951.

[225] C. Yu, H. Hong, S. Zhang, et al., “Identification of Key Genes and Pathways Involved in Microsatellite Instability in Colorectal Cancer,” Molecular Medicine Reports 19, no. 3 (2019): 2065–2076.

[226] B. Rao, J. Li, T. Ren, et al., “RPL19 Is a Prognostic Biomarker and Promotes Tumor Progression in Hepatocellular Carcinoma,” Frontiers in Cell and Developmental Biology 9 (2021): 686547.

[227] V. De Re, L. Alessandrini, G. Brisotto, et al., “HER2-CDH1 Interaction via Wnt/B-Catenin Is Associated With Patients' Survival in HER2-Positive Metastatic Gastric Adenocarcinoma,” Cancers 14, no. 5 (2022): 1266.

[228] H. C. Zheng, H. Xue, Y. Z. Jin, H. M. Jiang, and Z. G. Cui, “The Oncogenic Effects, Pathways, and Target Molecules of JC Polyoma Virus T Antigen in Cancer Cells,” Frontiers in Oncology 12 (2022): 744886.

[229] A. Ménoret, D. A. Drew, S. Miyamoto, M. Nakanishi, A. T. Vella, and D. W. Rosenberg, “Differential Proteomics Identifies PDIA3 as a Novel Chemoprevention Target in Human Colon Cancer Cells,” Molecular Carcinogenesis 53, no. Suppl 1 (2014): E11–E22.

[230] G. Kan, Z. Wang, C. Sheng, et al., “Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells,” Advanced Science 8, no. 10 (2021): 2004344.

[231] Y. Chen, Y. Mu, Q. Guan, et al., “RPL22L1, a Novel Candidate Oncogene Promotes Temozolomide Resistance by Activating STAT3 in Glioblastoma,” Cell Death & Disease 14, no. 11 (2023): 757.

[232] X. Yi, C. Zhang, B. Liu, et al., “Ribosomal Protein L22-Like1 Promotes Prostate Cancer Progression by Activating PI3K/Akt/mTOR Signalling Pathway,” Journal of Cellular and Molecular Medicine 27, no. 3 (2023): 403–411.

[233] Y. Wu, N. Yao, B. Du, et al., “Ribosomal Protein L22 Like 1: a Promising Biomarker for Lung Adenocarcinoma,” Journal of Cancer 15, no. 9 (2024): 2549–2560.

[234] C. Li, X. Du, H. Zhang, and S. Liu, “Knockdown of Ribosomal Protein L22-Like 1 Arrests the Cell Cycle and Promotes Apoptosis in Colorectal Cancer,” CytoJournal 21 (2024): 45.

[235] D. Zhang, Y. Zhou, Y. Ma, et al., “Ribosomal Protein L22-Like1 (RPL22L1) Mediates Sorafenib Sensitivity via ERK in Hepatocellular Carcinoma,” Cell Death Discovery 8, no. 1 (2022): 365.

[236] H. Kang, M. C. Choi, S. Kim, et al., “USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma,” Cancers 13, no. 16 (2021): 3976.

[237] M. Yang, Y. Zhou, H. Deng, et al., “Ribosomal Protein L23 Drives the Metastasis of Hepatocellular Carcinoma via Upregulating MMP9,” Frontiers in Oncology 11 (2021): 779748.

[238] I. R. Chen, C. C. Huang, S. J. Tu, et al., “Dysregulation of Immune Cell Subpopulations in Atypical Hemolytic Uremic Syndrome,” International Journal of Molecular Sciences 24, no. 12 (2023): 10007.

[239] J. Wang, Z. Q. Zhang, F. Q. Li, et al., “Triptolide Interrupts rRNA Synthesis and Induces the RPL23‑MDM2‑p53 Pathway to Repress Lung Cancer Cells,” Oncology Reports 43, no. 6 (2020): 1863–1874.

[240] S. R. Stott, S. J. Randle, S. Al Rawi, et al., “Loss of FBXO7 Results in a Parkinson's-Like Dopaminergic Degeneration via an RPL23-MDM2-TP53 Pathway,” Journal of Pathology 249, no. 2 (2019): 241–254.

[241] Z. Zhang, Q. Wu, M. Fang, et al., “HERC3 Directly Targets RPL23A for Ubiquitination Degradation and Further Regulates Colorectal Cancer Proliferation and the Cell Cycle,” International Journal of Biological Sciences 18, no. 8 (2022): 3282–3297.

[242] Y. Z. Zhang, A. Zeb, and L. F. Cheng, “Exploring the Molecular Mechanism of Hepatitis Virus Inducing Hepatocellular Carcinoma by Microarray Data and Immune Infiltrates Analysis,” Frontiers in Immunology 13 (2022): 1032819.

[243] H. T. Gazda, M. Preti, M. R. Sheen, et al., “Frameshift Mutation in p53 Regulator RPL26 Is Associated With Multiple Physical Abnormalities and a Specific Pre-Ribosomal RNA Processing Defect in Diamond-Blackfan Anemia,” Human Mutation 33, no. 7 (2012): 1037–1044.

[244] C. Du, T. Wang, J. Jia, et al., “Suppression of RPL34 Inhibits Tumor Cell Proliferation and Promotes Apoptosis in Glioblastoma,” Applied Biochemistry and Biotechnology 194, no. 8 (2022): 3494–3506.

[245] H. Fan, J. Li, Y. Jia, et al., “Silencing of Ribosomal Protein L34 (RPL34) Inhibits the Proliferation and Invasion of Esophageal Cancer Cells,” Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 25, no. 7 (2017): 1061–1068.

[246] H. Liu, S. Liang, X. Yang, et al., “RNAi-Mediated RPL34 Knockdown Suppresses the Growth of Human Gastric Cancer Cells,” Oncology Reports 34, no. 5 (2015): 2267–2272.

[247] S. Luo, J. Zhao, M. Fowdur, K. Wang, T. Jiang, and M. He, “Highly Expressed Ribosomal Protein L34 Indicates Poor Prognosis in Osteosarcoma and Its Knockdown Suppresses Osteosarcoma Proliferation Probably Through Translational Control,” Scientific Reports 6 (2016): 37690.

[248] X. Zhou, Z. Liu, T. He, et al., “DDX10 Promotes the Proliferation and Metastasis of Colorectal Cancer Cells via Splicing RPL35,” Cancer Cell International 22, no. 1 (2022): 58.

[249] P. Y. Liu, A. E. Tee, G. Milazzo, et al., “The Long Noncoding RNA lncNB1 Promotes Tumorigenesis by Interacting With Ribosomal Protein RPL35,” Nature Communications 10, no. 1 (2019): 5026.

[250] F. Wu, D. Sun, Y. Liao, K. Shang, and C. Lu, “RPL35A Is a Key Promotor Involved in the Development and Progression of Gastric Cancer,” Cancer Cell International 21, no. 1 (2021): 497.

[251] D. M. Gianferante, M. W. Wlodarski, E. Atsidaftos, et al., “Genotype-Phenotype Association and Variant Characterization in Diamond-Blackfan Anemia Caused by Pathogenic Variants in RPL35A,” Haematologica 106, no. 5 (2021): 1303–1310.

[252] Y. W. Hu, C. M. Kang, J. J. Zhao, et al., “LncRNA PLAC2 Down-Regulates RPL36 Expression and Blocks Cell Cycle Progression in Glioma Through a Mechanism Involving STAT1,” Journal of Cellular and Molecular Medicine 22, no. 1 (2018): 497–510.

[253] T. Furlan, A. Kirchmair, N. Sampson, et al., “MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-Resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors,” American Journal of Pathology 191, no. 6 (2021): 1094–1107.

[254] L. Zhao, Y. Tang, J. Yang, et al., “Integrative Analysis of Circadian Clock With Prognostic and Immunological Biomarker Identification in Ovarian Cancer,” Frontiers in Molecular Biosciences 10 (2023): 1208132.

[255] H. Engqvist, T. Z. Parris, A. Kovács, et al., “Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry,” Frontiers in Oncology 10 (2020): 162.

[256] I. Salgado, E. Prado Montes de Oca, I. Chairez, et al., “Deep Learning Techniques to Characterize the RPS28P7 Pseudogene and the Metazoa-SRP Gene as Drug Potential Targets in Pancreatic Cancer Patients,” Biomedicines 12, no. 2 (2024): 395.

[257] Q. Zhou, Z. Hou, S. Zuo, et al., “LUCAT1 Promotes Colorectal Cancer Tumorigenesis by Targeting the Ribosomal Protein L40-MDM2-p53 Pathway Through Binding With UBA52,” Cancer science 110, no. 4 (2019): 1194–1207.

[258] J. Park, J. Wu, K. J. Szkop, et al., “SMYD5 Methylation of rpL40 Links Ribosomal Output to Gastric Cancer,” Nature 632, no. 8025 (2024): 656–663.

[259] B. Miao, L. Ge, C. He, et al., “SMYD5 Is a Ribosomal Methyltransferase That Catalyzes RPL40 Lysine Methylation to Enhance Translation Output and Promote Hepatocellular Carcinoma,” Cell Research 34, no. 9 (2024): 648–660.

[260] X. Lin, L. Guo, X. Lin, Y. Wang, and G. Zhang, “Expression and Prognosis Analysis of Mitochondrial Ribosomal Protein Family in Breast Cancer,” Scientific Reports 12, no. 1 (2022): 10658.

[261] X. Y. Li, X. Y. He, H. Zhao, L. Qi, and J. J. Lu, “Identification of a Novel Therapeutic Target for Lung Cancer: Mitochondrial Ribosome Protein L9,” Pathology – Research and Practice 248 (2023): 154625.

[262] J. Yang, Z. Chen, N. Liu, and Y. Chen, “Ribosomal Protein L10 in Mitochondria Serves as a Regulator for ROS Level in Pancreatic Cancer Cells,” Redox Biology 19 (2018): 158–165.

[263] X. Ji, T. Zhang, J. Sun, et al., “UBASH3B-Mediated MRPL12 Y60 Dephosphorylation Inhibits LUAD Development by Driving Mitochondrial Metabolism Reprogramming,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 268.

[264] X. Ji, Z. Yang, C. Li, et al., “Mitochondrial Ribosomal Protein L12 Potentiates Hepatocellular Carcinoma by Regulating Mitochondrial Biogenesis and Metabolic Reprogramming,” Metabolism: Clinical and Experimental 152 (2024): 155761.

[265] Y. Hu, Y. Liu, C. Ma, and K. Ai, “MRPL12 Acts as a Novel Prognostic Biomarker Involved in Immune Cell Infiltration and Tumor Progression of Lung Adenocarcinoma,” International Journal of Molecular Sciences 24, no. 3 (2023): 2762.

[266] X. Ji, F. Xue, Y. Wang, et al., “MRPL12 K163 Acetylation Inhibits ccRCC via Driving Mitochondrial Metabolic Reprogramming,” Cell Death & Disease 16, no. 1 (2025): 646.

[267] S. Sun, D. Su, T. Dong, et al., “Mitochondrial Ribosomal Protein L12 Mediates Metabolic Reorganization in Clear Cell Renal Cell Carcinoma by Regulating Mitochondrial Biosynthesis,” Cell Communication and Signaling 23, no. 1 (2025): 435.

[268] O. Liu, Y. Hu, S. Wang, et al., “MRPL13 Enhances Mitochondrial Function and Promotes Tumor Progression in Ovarian Cancer by Inhibiting mPTP Opening via SLC25A6,” Cell Death & Disease 16, no. 1 (2025): 634.

[269] Y. K. Lee, J. J. Lim, U. Jeoun, et al., “Lactate-Mediated Mitoribosomal Defects Impair Mitochondrial Oxidative Phosphorylation and Promote Hepatoma Cell Invasiveness,” Journal of Biological Chemistry 292, no. 49 (2017): 20208–20217.

[270] Y. Liang, S. He, Y. Tan, et al., “In Silico Analyses of Pan-Squamous Cell Carcinoma Unveiled the Immunological Implications of MRPL13, Which Had Previously Been Under-Recognized,” Heliyon 10, no. 1 (2024): e23582.

[271] H. J. Kim, Q. K. Nguyen, S. N. Jung, et al., “Mitochondrial Ribosomal Protein L14 Promotes Cell Growth and Invasion by Modulating Reactive Oxygen Species in Thyroid Cancer,” Clinical and Experimental Otorhinolaryngology 16, no. 2 (2023): 184–197.

[272] Y. Zeng, Y. Shi, L. Xu, et al., “Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer,” Frontiers in Oncology 11 (2021): 656172.

[273] H. Xu, R. Zou, F. Li, et al., “MRPL15 Is a Novel Prognostic Biomarker and Therapeutic Target for Epithelial Ovarian Cancer,” Cancer Medicine 10, no. 11 (2021): 3655–3673.

[274] L. Del Puerto-Nevado, A. Santiago-Hernandez, S. Solanes-Casado, et al., “Diabetes-Mediated Promotion of Colon Mucosa Carcinogenesis Is Associated With Mitochondrial Dysfunction,” Molecular Oncology 13, no. 9 (2019): 1887–1897.

[275] H. Li, W. Ouyang, Y. Long, et al., “MRPL18 Promotes Breast Cancer Progression: Connecting Mitochondrial Ribosomal Protein to Immune Response,” Oncology Research 33, no. 9 (2025): 2549–2571.

[276] X. Li, M. Wang, S. Li, et al., “HIF-1-Induced Mitochondrial Ribosome Protein L52: A Mechanism for Breast Cancer Cellular Adaptation and Metastatic Initiation in Response to Hypoxia,” Theranostics 11, no. 15 (2021): 7337–7359.

[277] A. Midde, N. Arri, T. Kristian, et al., “Targeting Mitochondrial Ribosomal Protein Expression by Andrographolide and Melatonin for Colon Cancer Treatment,” Cancer Letters 619 (2025): 217647.

[278] S. Min, Y. K. Lee, J. Hong, et al., “MRPS31 Loss Is a Key Driver of Mitochondrial Deregulation and Hepatocellular Carcinoma Aggressiveness,” Cell Death & Disease 12, no. 11 (2021): 1076.

[279] J. Pelletier, G. Thomas, and S. Volarević, “Ribosome Biogenesis in Cancer: New Players and Therapeutic Avenues,” Nature Reviews Cancer 18, no. 1 (2018): 51–63.

[280] J. Zhu, N. Wen, W. Chen, and H. Yu, “Mitochondrial Ribosomal Proteins: Potential Targets for Cancer Prognosis and Therapy,” Frontiers in Oncology 15 (2025): 1586137.

[281] J. Chen, Y. Wei, Q. Feng, et al., “Ribosomal Protein S15A Promotes Malignant Transformation and Predicts Poor Outcome in Colorectal Cancer Through Misregulation of p53 Signaling Pathway,” International Journal of Oncology 48, no. 4 (2016): 1628–1638.

[282] P. Jaako, J. Flygare, K. Olsson, et al., “Mice With Ribosomal Protein S19 Deficiency Develop Bone Marrow Failure and Symptoms Like Patients With Diamond-Blackfan Anemia,” Blood 118, no. 23 (2011): 6087–6096.

[283] J. C. Ulirsch, J. M. Verboon, S. Kazerounian, et al., “The Genetic Landscape of Diamond-Blackfan Anemia,” American Journal of Human Genetics 103, no. 6 (2018): 930–947.

[284] M. Haddach, M. K. Schwaebe, J. Michaux, et al., “Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics,” ACS Medicinal Chemistry Letters 3, no. 7 (2012): 602–606.

[285] M. J. Bywater, G. Poortinga, E. Sanij, et al., “Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53,” Cancer Cell 22, no. 1 (2012): 51–65.

[286] D. Drygin, A. Lin, J. Bliesath, et al., “Targeting RNA Polymerase I With an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth,” Cancer Research 71, no. 4 (2011): 1418–1430.

[287] D. Drygin, A. Siddiqui-Jain, S. O'Brien, et al., “Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis,” Cancer Research 69, no. 19 (2009): 7653–7661.

[288] R. Cornelison, Z. C. Dobbin, A. A. Katre, et al., “Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer,” Clinical Cancer Research 23, no. 21 (2017): 6529–6540.

[289] J. Hilton, K. Gelmon, P. L. Bedard, et al., “Results of the Phase I CCTG IND.231 Trial of CX-5461 in Patients With Advanced Solid Tumors Enriched for DNA-Repair Deficiencies,” Nature Communications 13, no. 1 (2022): 3607.

[290] K. Cui, L. Gong, H. Zhang, et al., “EXOSC8 Promotes Colorectal Cancer Tumorigenesis via Regulating Ribosome Biogenesis-Related Processes,” Oncogene 41, no. 50 (2022): 5397–5410.

[291] H. Dong, Q. Liao, B. Xie, et al., “Nucleolar Stress Promotes and Cooperates With Ferroptosis to Suppress Cancer Growth,” Science China Life Sciences 66, no. 11 (2023): 2684–2687.

[292] Q. Hao, J. Wang, Y. Chen, et al., “Dual Regulation of p53 by the Ribosome Maturation Factor SBDS,” Cell Death & Disease 11, no. 3 (2020): 197.

[293] C. Jiang, L. Sun, S. Wen, et al., “BRIX1 Promotes Ribosome Synthesis and Enhances Glycolysis by Selected Translation of GLUT1 in Colorectal Cancer,” Journal of Gene Medicine 26, no. 1 (2024): e3632.

[294] Y. Gan, Q. Hao, T. Han, et al., “Targeting BRIX1 via Engineered Exosomes Induces Nucleolar Stress to Suppress Cancer Progression,” Advanced Science 11, no. 47 (2024): e2407370.

[295] J. Hai, S. Sakashita, G. Allo, et al., “Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models,” Journal of Thoracic Oncology 10, no. 8 (2015): 1172–1180.

[296] B. Wang, J. Gao, Z. Zhao, et al., “Identification of a Small-Molecule RPL11 Mimetic That Inhibits Tumor Growth by Targeting MDM2-p53 Pathway,” Molecular Medicine 28, no. 1 (2022): 109.

[297] C. Tovar, B. Graves, K. Packman, et al., “MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models,” Cancer Research 73, no. 8 (2013): 2587–2597.

[298] S. Dutt, A. Narla, K. Lin, et al., “Haploinsufficiency for Ribosomal Protein Genes Causes Selective Activation of p53 in Human Erythroid Progenitor Cells,” Blood 117, no. 9 (2011): 2567–2576.

[299] K. M. Goudarzi, M. Nistér, and M. S. Lindström, “mTOR Inhibitors Blunt the p53 Response to Nucleolar Stress by Regulating RPL11 and MDM2 Levels,” Cancer Biology & Therapy 15, no. 11 (2014): 1499–1514.

[300] M. S. Matter, T. Decaens, J. B. Andersen, and S. S. Thorgeirsson, “Targeting the mTOR Pathway in Hepatocellular Carcinoma: Current State and Future Trends,” Journal of Hepatology 60, no. 4 (2014): 855–865.

[301] C. Zhou, C. Liu, W. Liu, et al., “SLFN11 Inhibits Hepatocellular Carcinoma Tumorigenesis and Metastasis by Targeting RPS4X via mTOR Pathway,” Theranostics 10, no. 10 (2020): 4627–4643.

[302] B. Magnuson, B. Ekim, and D. C. Fingar, “Regulation and Function of Ribosomal Protein S6 Kinase (S6K) Within mTOR Signalling Networks,” Biochemical Journal 441, no. 1 (2012): 1–21.

[303] L. Deng, G. Qian, S. Zhang, et al., “Inhibition of mTOR Complex 1/p70 S6 Kinase Signaling Elevates PD-L1 Levels in Human Cancer Cells Through Enhancing Protein Stabilization Accompanied With Enhanced β-TrCP Degradation,” Oncogene 38, no. 35 (2019): 6270–6282.

[304] Z. Xu, C. C. Chang, M. Li, et al., “ILT3.Fc-CD166 Interaction Induces Inactivation of p70 S6 Kinase and Inhibits Tumor Cell Growth,” Journal of Immunology 200, no. 3 (2018): 1207–1219.

[305] M. Artemenko, S. S. W. Zhong, S. K. Y. To, and A. S. T. Wong, “p70 S6 Kinase as a Therapeutic Target in Cancers: More Than Just an mTOR Effector,” Cancer Letters 535 (2022): 215593.

[306] A. Pecoraro, P. Carotenuto, B. Franco, R. De Cegli, G. Russo, and A. Russo, “Role of uL3 in the Crosstalk Between Nucleolar Stress and Autophagy in Colon Cancer Cells,” International Journal of Molecular Sciences 21, no. 6 (2020): 2143.

[307] A. Pecoraro, P. Carotenuto, G. Russo, and A. Russo, “Ribosomal Protein uL3 Targets E2F1 and Cyclin D1 in Cancer Cell Response to Nucleolar Stress,” Scientific Reports 9, no. 1 (2019): 15431.

[308] A. Pecoraro, A. Virgilio, V. Esposito, A. Galeone, G. Russo, and A. Russo, “uL3 Mediated Nucleolar Stress Pathway as a New Mechanism of Action of Antiproliferative G-Quadruplex TBA Derivatives in Colon Cancer Cells,” Biomolecules 10, no. 4 (2020): 583.

[309] A. Russo, S. Maiolino, V. Pagliara, et al., “Enhancement of 5-FU Sensitivity by the Proapoptotic rpL3 Gene in p53 Null Colon Cancer Cells Through Combined Polymer Nanoparticles,” Oncotarget 7, no. 48 (2016): 79670–79687.

[310] A. Russo, A. Saide, R. Cagliani, M. Cantile, G. Botti, and G. Russo, “rpL3 Promotes the Apoptosis of p53 Mutated Lung Cancer Cells by Down-Regulating CBS and NFκB Upon 5-FU Treatment,” Scientific Reports 6 (2016): 38369.

[311] S. Violette, L. Poulain, E. Dussaulx, et al., “Resistance of Colon Cancer Cells to Long-Term 5-Fluorouracil Exposure Is Correlated to the Relative Level of Bcl-2 and Bcl-X(L) in Addition to Bax and p53 Status,” International Journal of Cancer 98, no. 4 (2002): 498–504.

[312] Q. Zhu, N. B. Wan, H. W. Deng, et al., “SEC. 14L3 Plays a Tumor-Suppressive Role in Breast Cancer Through a Wnt/β-Catenin-Related Way,” Experimental Cell Research 417, no. 1 (2022): 113161.

[313] Z. Jiang, G. Yang, G. Wang, et al., “SEC. 14L3 Knockdown Inhibited Clear Cell Renal Cell Carcinoma Proliferation, Metastasis and Sunitinib Resistance Through an SEC. 14L3/RPS3/NFκB Positive Feedback Loop,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 288.

[314] X. Li, Z. Yang, S. Huang, et al., “FTO Inhibition Represses B-Cell Acute Lymphoblastic Leukemia Progression by Inducing Nucleolar Stress and Mitochondrial Dysfunction,” Free Radical Biology and Medicine 238 (2025): 507–521.

[315] S. L. Jiang, J. L. Mo, J. Peng, et al., “Targeting Translation Regulators Improves Cancer Therapy,” Genomics 113, no. 1 Pt 2 (2021): 1247–1256.

[316] L. Xia, D. Zhang, R. Du, et al., “miR-15b and miR-16 Modulate Multidrug Resistance by Targeting BCL2 in Human Gastric Cancer Cells,” International Journal of Cancer 123, no. 2 (2008): 372–379.

[317] A. M. M. T. Reza, Y. J. Choi, Y. G. Yuan, J. Das, H. Yasuda, and J. H. Kim, “MicroRNA-7641 Is a Regulator of Ribosomal Proteins and a Promising Targeting Factor to Improve the Efficacy of Cancer Therapy,” Scientific Reports 7, no. 1 (2017): 8365.

[318] C. Li, M. Ge, Y. Yin, M. Luo, and D. Chen, “Silencing Expression of Ribosomal Protein L26 and L29 by RNA Interfering Inhibits Proliferation of Human Pancreatic Cancer PANC-1 Cells,” Molecular and Cellular Biochemistry 370, no. 1–2 (2012): 127–139.

[319] C. Li, D. Chen, M. Luo, M. Ge, and J. Zhu, “Knockdown of Ribosomal Protein L39 by RNA Interference Inhibits the Growth of Human Pancreatic Cancer Cells In Vitro and In Vivo,” Biotechnology Journal 9, no. 5 (2014): 652–663.

[320] B. R. Kao, A. Malerba, N. B. Lu-Nguyen, et al., “Knockdown of Muscle-Specific Ribosomal Protein L3-Like Enhances Muscle Function in Healthy and Dystrophic Mice,” Nucleic Acid Therapeutics 31, no. 6 (2021): 457–464.

[321] H. Wu, X. Zhu, H. Zhou, M. Sha, J. Ye, and H. Yu, “Mitochondrial Ribosomal Proteins and Cancer,” Medicina (Kaunas, Lithuania) 61, no. 1 (2025): 96.

[322] J. M. Bacon, J. L. Jones, G. S. Liu, J. L. Dickinson, and K. Raspin, “Mitochondrial Ribosomal Proteins in Metastasis and Their Potential Use as Prognostic and Therapeutic Targets,” Cancer and Metastasis Reviews 43, no. 4 (2024): 1119–1135.

[323] B. Ózsvári, F. Sotgia, and M. P. Lisanti, “First-in-Class Candidate Therapeutics That Target Mitochondria and Effectively Prevent Cancer Cell Metastasis: Mitoriboscins and TPP Compounds,” Aging 12, no. 11 (2020): 10162–10179.

[324] D. Sokolov, N. Sharda, B. Giri, et al., “Melatonin and Andrographolide Synergize to Inhibit the Colospheroid Phenotype by Targeting Wnt/Beta-Catenin Signaling,” Journal of Pineal Research 73, no. 1 (2022): e12808.

[325] V. Banerjee, N. Sharda, J. Huse, et al., “Synergistic Potential of Dual Andrographolide and Melatonin Targeting of Metastatic Colon Cancer Cells: Using the Chou-Talalay Combination Index Method,” European Journal of Pharmacology 897 (2021): 173919.

[326] E. Martín-Encinas, A. Selas, F. Palacios, and C. Alonso, “The Design and Discovery of Topoisomerase I Inhibitors as Anticancer Therapies,” Expert Opinion on Drug Discovery 17, no. 6 (2022): 581–601.

[327] S. Yamada, Y. Kitai, T. Tadokoro, et al., “Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates With DAMP Secretion and Antitumor Immune Activation,” Journal of Immunology 209, no. 1 (2022): 171–179.

[328] R. Takahashi, K. Yamamoto, H. Toya, et al., “A Selective RPL15 PROTAC Degrader Enhances Anti-PD-1 Immunotherapy in a Murine Melanoma Tumor Model,” Oncogene 44, no. 50 (2025): 4846–4854.

[329] C. Bailly and G. Vergoten, “Interaction of Camptothecin Anticancer Drugs With Ribosomal Proteins L15 and L11: A Molecular Docking Study,” Molecules 28, no. 4 (2023): 1828.

[330] W. S. Ahn, T. S. Kim, Y. J. Park, Y. K. Park, H. D. Kim, and J. Kim, “Production, Characterization, and Epitope Mapping of Monoclonal Antibodies of Ribosomal Protein S3 (rpS3),” Animal Cells and Systems 25, no. 5 (2021): 323–336.

[331] N. Wu, F. Lin, J. Ji, et al., “Mitochondrial Oxidative Stress Related LncRNA Predict Cervical Cancer Prognosis and Immunotherapy Response: Molecular Structure and Protein Interaction of Ribosomal Protein L34,” International Journal of Biological Macromolecules 299 (2025): 140145.

[332] Y. Gao, Y. Yu, H. Wu, Z. Xiao, and J. Li, “Mitochondrial Ribosomal Protein S24 Is Associated With Immunosuppressive Microenvironment and Cold Tumor in Lung Adenocarcinoma,” Heliyon 10, no. 7 (2024): e29171.

[333] X. Kuai, C. Wei, X. He, F. Wang, C. Wang, and J. Ji, “The Potential Value of RPS27A in Prognosis and Immunotherapy: From Pan-Cancer Analysis to Hepatocellular Carcinoma Validation,” ImmunoTargets and Therapy 13 (2024): 673–690.

[334] M. Koga, S. Shichijo, A. Yamada, et al., “Identification of Ribosomal Proteins S2 and L10a as Tumor Antigens Recognized by HLA-A26-Restricted CTL,” Tissue Antigens 61, no. 2 (2003): 136–145.

[335] K. Kuroda, M. Takenoyama, T. Baba, et al., “Identification of Ribosomal Protein L19 as a Novel Tumor Antigen Recognized by Autologous Cytotoxic T Lymphocytes in Lung Adenocarcinoma,” Cancer Science 101, no. 1 (2010): 46–53.

[336] P. Jaako, S. Debnath, K. Olsson, et al., “Gene Therapy Cures the Anemia and Lethal Bone Marrow Failure in a Mouse Model of RPS19-Deficient Diamond-Blackfan Anemia,” Haematologica 99, no. 12 (2014): 1792–1798.

[337] Y. Liu, M. Dahl, S. Debnath, et al., “Successful Gene Therapy of Diamond-Blackfan Anemia in a Mouse Model and Human CD34(+) Cord Blood Hematopoietic Stem Cells Using a Clinically Applicable Lentiviral Vector,” Haematologica 107, no. 2 (2022): 446–456.

[338] Y. Giménez, M. Palacios, R. Sánchez-Domínguez, et al., “Lentivirus-Mediated Gene Therapy Corrects Ribosomal Biogenesis and Shows Promise for Diamond Blackfan Anemia,” JCI Insight 9, no. 10 (2024): e171650.

[339] Y. F. Zhang, B. C. Zhang, A. R. Zhang, et al., “Co-Transduction of Ribosomal Protein L23 Enhances the Therapeutic Efficacy of Adenoviral-Mediated p53 Gene Transfer in Human Gastric Cancer,” Oncology Reports 30, no. 4 (2013): 1989–1995.

[340] H. Fang, J. Kang, R. Du, et al., “Growth Inhibitory Effect of Adenovirus-Mediated Tissue-Targeted Expression of Ribosomal Protein L23 on Human Colorectal Carcinoma Cells,” Oncology Reports 34, no. 2 (2015): 763–770.

[341] K. Engeland, “Cell Cycle Regulation: p53-p21-RB Signaling,” Cell Death & Differentiation 29, no. 5 (2022): 946–960.

[342] P. Vikhreva, G. Melino, and I. Amelio, “p73 Alternative Splicing: Exploring a Biological Role for the C-Terminal Isoforms,” Journal of Molecular Biology 430, no. 13 (2018): 1829–1838.

[343] H. Ramos, L. Raimundo, and L. Saraiva, “p73: From the p53 Shadow to a Major Pharmacological Target in Anticancer Therapy,” Pharmacological Research 162 (2020): 105245.

[344] Y. Zhang, M. N. O'Leary, S. Peri, et al., “Ribosomal Proteins Rpl22 and Rpl22l1 Control Morphogenesis by Regulating Pre-mRNA Splicing,” Cell Reports 18, no. 2 (2017): 545–556.

[345] S. Ntoufa, M. Gerousi, S. Laidou, et al., “RPS15 Mutations Rewire RNA Translation in Chronic Lymphocytic Leukemia,” Blood Advances 5, no. 13 (2021): 2788–2792.

[346] W. Wang, N. Albadari, Y. Du, et al., “MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future,” Pharmacological Reviews 76, no. 3 (2024): 414–453.

[347] Z. Cai, J. Wang, Y. Li, et al., “Overexpressed Cyclin D1 and CDK4 Proteins Are Responsible for the Resistance to CDK4/6 Inhibitor in Breast Cancer That Can Be Reversed by PI3K/mTOR Inhibitors,” Science China Life Sciences 66, no. 1 (2023): 94–109.

[348] N. Guedeney, M. Cornu, F. Schwalen, C. Kieffer, and A. S. Voisin-Chiret, “PROTAC Technology: A New Drug Design for Chemical Biology With Many Challenges in Drug Discovery,” Drug Discovery Today 28, no. 1 (2023): 103395.

[349] L. M. Da Costa, I. Marie, and T. M. Leblanc, “Diamond-Blackfan Anemia,” Hematology 2021, no. 1 (2021): 353–360.

[350] X. Liu, Z. Xu, Y. Che, et al., “Mechanical Agitation-Assisted Transmembrane Drug Delivery by Magnetically Powered Spiky Nanorobots,” Research; A Journal of Science and Its Applications 8 (2025): 0768.

[351] B. Lau, Z. Huang, N. Kellner, et al., “Mechanism of 5S RNP Recruitment and Helicase-Surveilled rRNA Maturation During Pre-60S Biogenesis,” EMBO Reports 24, no. 7 (2023): e56910.

[352] M. Zhang, X. Xu, L. Su, et al., “Oral Administration of Sophora Flavescens-Derived Exosomes-Like Nanovesicles Carrying CX5461 Ameliorates DSS-Induced Colitis in Mice,” Journal of Nanobiotechnology 22, no. 1 (2024): 607.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).